Andere talen Passage Bio, Inc.

Aandelen

PASG

US7027121000

Geschatte realtime Cboe BZX Andere beurzen 21:20:20 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,31 ^USD	+7,38%		+11,30%	+26,73%

04/03	Passage Bio, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	Passage Bio zegt dat de gegevens van fase 1/2-onderzoek naar een therapie voor dementie de verwachtingen overtroffen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

PASSAGE BIO TO PRESENT AT CHARDAN'S 8TH ANNUAL GENETIC MEDICINES AND CELL THERAPY MANUFACTURING SUMMIT	23/04
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	22/04
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program	05/03
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	04/03
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights	04/03
Passage Bio to Participate in Upcoming Investor Conferences	27/02
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
Passage Bio : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	29/12
Passage Bio Says Data From Phase 1/2 Trial of Dementia Therapy Exceeded Expectations	20/12
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	20/12
Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	20/12
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)	17/11
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights	13/11
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference	30-10-23
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20-10-23
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20-10-23
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09-10-23
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference	25-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Passage Bio, Inc.

Aandelen

PASG

US7027121000

Andere talen

Filters